News and Trends 12 May 2025 Pharma giants pull back on AAV research: what’s next for the gene therapy space? Biopharmas have been scaling back on AAV research for sometime now. Find out why and what’s on the horizon for drug delivery methods. May 12, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Sponsored by KBI Biopharma 5 Nov 2024 Unlocking AAV gene therapy potential: The role of successful characterization Explore the role and challenges of AAV characterization, the significance of capsid filling, and the best methods to enhance gene therapy. November 5, 2024 - 8 minutesmins - By Ute Boronowsky Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2024 Vironexis’ AAV vector approach: The next frontier in cancer immunology? Delve into Vironexis’ launch with a pipeline of 10 cancer drug candidates built around its AAV vectors platform. September 16, 2024 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 9 Feb 2023 TILT Biotherapeutics closes €22M financing for oncology immunotherapy trials TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, has closed its €22 million ($23.8 million) round. This follows on from the first close of €10 million in June 2022. The financing was led by Finland’s Lifeline Ventures, an early-stage venture capital firm founded by serial entrepreneurs. The funding will be used to advance […] February 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2022 Syncona to acquire Applied Genetic Technologies Corporation Healthcare company Syncona Limited says its newly established portfolio company has agreed to acquire, by a tender offer, all outstanding shares of Applied Genetic Technologies Corporation (AGTC). AGTC is a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an […] October 24, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Startup Scout 8 Sep 2022 Stratosvir is overcoming the viral immunotherapy delivery bottleneck The U.K. startup Stratosvir is working to tackle the barriers to developing viral immunotherapies for cancer, including allowing intravenous delivery and making it possible to dose multiple times. Cancer immunotherapies have made great strides in the last decade, with some of the most important advances including CAR-T cell therapy and checkpoint inhibitors. One oncology field […] September 8, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2022 TILT Biotherapeutics raises $10M to push ahead on cancer immunotherapies TILT Biotherapeutics (TILT), a clinical-stage Finnish biotech company developing cancer immunotherapies, has completed the first close of its financing round, raising $10.7 million. It was led by Lifeline Ventures and joined by Tesi (Finnish Industry Investment Ltd). The funding will be used to advance phase I/II programs in Europe and the U.S., using TILT-123 plus […] June 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email